¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå : À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, À¯Åë ä³Îº°, Áö¿ªº°
Global Epinephrine Autoinjector Market, By Type, By End User, By Distribution Channel, By Geography
»óǰÄÚµå : 1708601
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,233,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,697,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,853,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ¼¼°è ½ÃÀåÀº 2025³â¿¡ 27¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 49¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2032³â µ¿¾È 8.8%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 27¾ï 4,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR 8.80% 2032³â ±Ý¾× ¿¹Ãø 49¾ï 5,000¸¸ ´Þ·¯
±×¸². ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ¼¼°è ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2025³â
Global Epinephrine Autoinjector Market-IMG1

¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â´Â ¾Æ³ªÇʶô½Ã½º¸¦ Æ÷ÇÔÇÑ ¾Ë·¹¸£±â ¹ÝÀÀÀÇ ÀÀ±ÞÄ¡·á¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â ÀÏȸ¿ë ÀÚµ¿ÁÖ»ç±âÀÔ´Ï´Ù. ¾Æ³ªÇʶô½Ã½º´Â ƯÁ¤ À½½Ä, ÀǾàǰ, ¹ú·¹ ¹°¸², ±âŸ ¾Ë·¹¸£°Õ¿¡ ´ëÇÑ ±Ø½ÉÇÑ ¾Ë·¹¸£±â ¹ÝÀÀÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â »ý¸íÀ» À§ÇùÇÏ´Â »óÅÂÀÔ´Ï´Ù. ¾Æ³ªÇʶô½Ã½ºÀÇ Áõ»óÀ¸·Î´Â Ç÷¾Ð ÀúÇÏ, ÀÔ°ú ¸ñÀÇ ºÎÁ¾, ¹ßÁø, È£Èí°ï¶õ, ¼îÅ© µîÀÌ ÀÖ½À´Ï´Ù. ¾Æ³ªÇʶô½Ã½ºÀÇ °æ¿ì, Áõ»óÀÇ ÁøÇàÀ» ¾ïÁ¦Çϱâ À§ÇØ ¿¡Çdz×ÇÁ¸°À» Àû½Ã¿¡ Åõ¿©ÇØ¾ß ÇÕ´Ï´Ù. ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â´Â ÁÖ»ç±â¿¡ ºñÇØ ¿¡Çdz×ÇÁ¸°À» ½Å¼ÓÇÏ°Ô ÀÚµ¿ Åõ¿©ÇÒ ¼ö ÀÖ¾î Àθí ÇÇÇØÀÇ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

FAAN(The Food Allergy and Anaphylaxis Network)ÀÌ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­¸¸ ¿¬°£ 5¸¸ °ÇÀÇ ¾Æ³ªÇʶô½Ã½º°¡ ¹ß»ýÇϸç, ±× Áß 150-200¸íÀÌ »ç¸ÁÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ±× Áß 150-200°ÇÀÌ »ç¸Á¿¡ À̸£°í ÀÖ½À´Ï´Ù. ¾Ë·¹¸£±â¿Í °ü·ÃµÈ »ý¸íÀ» À§ÇùÇÏ´Â Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÷´Ü ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±âÀÇ °¡¿ë¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ ºñ¿ë°ú ½ÅÈï±¹ÀÇ ´ëü Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼±È£µµ°¡ ½ÃÀå ¼ºÀåÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. Çâ»óµÈ »ç¿ë ÆíÀǼº, Á¤È®¼º, ´õ ³ÐÀº Àû¿ë ¹üÀ§¸¦ °®Ãá Çõ½ÅÀûÀÎ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±âÀÇ °³¹ßÀº ÇâÈÄ ¸î ³â µ¿¾È Á¦Á¶¾÷ü¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀåÀº ±â¼ú ¹ßÀü, ¾Æ³ªÇʶô½Ã½º¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, »ç¿ëÀÚ Ä£È­ÀûÀÎ µðÀÚÀο¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇØ ÁÖ¸ñÇÒ ¸¸ÇÑ Ãß¼¼¸¦ ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. ¹Ù´Ã ¾ø´Â ´ëüǰ ¹× ÈÆ·Ã¿ë µðÁöÅÐ Çコ Ç÷§ÆûÀÌ °¢±¤À» ¹Þ°í ÀÖÀ¸¸ç, ȯÀÚÀÇ ÆíÀǼº°ú Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ½Ã½ºÅÛ ¹× °ø±Þ¸Á¿¡ ´ëÇÑ ÀûÀÀ·ÂÀ» ÇÊ¿ä·Î ÇÏ´Â ÆÒµ¥¹ÍÀÇ ¿µÇâÀ» ¹Þ¾Æ ÁøÈ­ÇÏ´Â »óȲ¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å, ±â±â ±â´É °³¼±, Àü·«Àû Á¦ÈÞ°¡ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀåÀÇ ¿ªÇÐÀ» Çü¼ºÇϰí ÀÖÀ¸¸ç, ±Þº¯ÇÏ´Â ÀÇ·á ȯ°æ¿¡¼­ À§Çè¿¡ óÇÑ °³Àΰú ÀÇ·á ¼­ºñ½º Á¦°øÀÚÀÇ ¿ä±¸¿¡ ºÎÀÀÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â)ÀÇ ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°è ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀåÀÇ ÁÖ¿ä ¾÷ü¸¦ ȸ»ç °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ÁÖ¿ä ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

ÁÖ¿ä ±â¾÷À¸·Î´Â Mylan, Teva Pharmaceutical, Impax Laboratories, Adamis Pharmaceuticals Corporation, Pfizer, ALK Abello, Lincoln Medical, Hospira, Sanofi, Kaleo µîÀÌ ÀÖ½À´Ï´Ù. Kaleo µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°è ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

¼¼°è ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀåÀ» ºÐ¼®ÇÒ ¶§ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÌÇØ°ü°èÀÚµéÀº ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå, À¯Çüº°, 2020-2032³â

Á¦6Àå ¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020-2032³â

Á¦7Àå ¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â

Á¦8Àå ¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå, Áö¿ªº°, 2020-2032³â

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¼½¼Ç

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Epinephrine Autoinjector Market is estimated to be valued at USD 2.74 Bn in 2025 and is expected to reach USD 4.95 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 2.74 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 8.80% 2032 Value Projection: USD 4.95 Bn
Figure. Global Epinephrine Autoinjector Market Share (%), By Region 2025
Global Epinephrine Autoinjector Market - IMG1

Epinephrine autoinjector is a single-use disposable automatic injection device that is intended for emergency treatment of allergic reactions including anaphylaxis. Anaphylaxis is a life-threatening condition that occur due to an extreme allergic reaction to certain foods, medicines, insects bites and other allergens. The symptoms of anaphylaxis include low blood pressure, swelling of the mouth or throat, rashes, breathing difficulty and shock. In case of anaphylaxis, epinephrine needs to be administered in a timely manner to curb the advancement of symptoms. Epinephrine autoinjectors enable rapid self-administration of epinephrine as compared to syringes, thereby, reducing the risk of casualty.

Market Dynamics:

Global epinephrine autoinjector market growth is driven by rising prevalence of anaphylaxis worldwide. According to the data published by FAAN (The Food Allergy and Anaphylaxis Network), 50,000 cases of anaphylaxis occur annually in the U.S. alone, out of which 150-200 result in death. Increased awareness regarding life-threatening conditions associated with allergies along with availability of advanced epinephrine autoinjector devices are fueling the market demand. However, cost of these devices and preference for alternative treatment options in developing nations limits the market growth. Development of innovative epinephrine autoinjectors with improved usability, accuracy and larger coverage area is expected to present lucrative opportunities for manufacturers in the coming years.

The epinephrine autoinjector market is witnessing notable trends, driven by advancements in technology, increased awareness of anaphylaxis, and a growing emphasis on user-friendly designs. Needle-free alternatives and digital health platforms for training are gaining prominence, enhancing patient comfort and accessibility. The market is also responding to the evolving landscape influenced by the pandemic, necessitating adaptability in healthcare systems and supply chains. Continuous innovation, improved device features, and strategic collaborations are further shaping the dynamics of the epinephrine autoinjector market, aiming to address the needs of at-risk individuals and healthcare providers in a rapidly changing healthcare environment.

Key features of the study:

This report provides in-depth analysis of the global epinephrine autoinjector market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global epinephrine autoinjector market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Mylan, Teva Pharmaceutical, Impax Laboratories, Adamis Pharmaceuticals Corporation, Pfizer, ALK Abello, Lincoln Medical, Hospira, Sanofi, and Kaleo

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global epinephrine autoinjector market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epinephrine autoinjector market

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Epinephrine Autoinjector Market- Impact of Coronavirus (COVID-19) Pandemic

5. Global Epinephrine Autoinjector Market, By Type, 2020-2032, (US$ Bn)

6. Global Epinephrine Autoinjector Market, By End User, 2020-2032, (US$ Bn)

7. Global Epinephrine Autoinjector Market, By Distribution Channel, 2020-2032, (US$ Bn)

8. Global Epinephrine Autoinjector Market, By Region, 2020-2032, (US$ Bn)

9. Competitive Landscape

10. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â